Relationship between cognitive performance and symptomatic profile in the quality of life of patients with schizophrenia spectrum disorders
Article Sidebar
Downloads
This work is licensed under a Creative Commons Attribution 3.0 Unported License.
Main Article Content
Abstract
Objective: To evaluate the association of psychopathological symptoms and cognitive functioning with the measures of subjective quality of life of a group of patients diagnosed with the schizophrenia spectrum.
Methodology: The study included 102 outpatients who met the DSM-IV-TR criteria for the diagnosis of schizophrenia spectrum disorders. The data were obtained by means of the Seville Questionnaire of Quality of Life (CSCV), the scale for the positive and negative schizophrenia syndrome (PANSS), the Beck Depression Inventory (BDI) as well as the state-trait Anxiety Inventory (STAI).
Results: The multiple regression analysis showed, on one hand, that favorable aspects of quality of life are affected by cognitive disorganization, positive, depressive and anxiety symptoms. On the other hand, the presence of emotional symptoms is strongly associated with unfavorable aspects, which suggests that this symptomatic dimension impairs the subjective perception of well-being of patients with schizophrenia spectrum disorders.
Conclusions: Psychopathological symptoms and cognitive function affect the subjective quality of life in patients with schizophrenia. If the aim of the treatment is to improve the perceived quality of life, the strategies should consider seeking the improvement symptoms of an emotional nature, such as depression / anxiety and emotional distress.
References
Tomida K, Takahashi N, Saito S, Maeno N, Iwamoto K, Yoshida K, et al. Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci. 2010; 64(1):62–9.
Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996; 94(2):118–24.
Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984; 10(3):388–98.
Skantze K, Malm U, Dencker SJ, May PRA, Corrigan P. Comparison of quality of life with standard of living in schizophrenic out-patients. Br J Psychiatry. 1992; 161(DEC.):797–801.
Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval Program Plann. 1983; 6(2):143–51.
Lehman AF. The well-being of chronic mental patients: Assessing their quality of life. Arch Gen Psychiatry. 1983; 40(4):369–73.
Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: The impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004; 65(7):932–9.
Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005; 38(6):320–6.
Kugo A, Terada S, Ishizu H, Takeda T, Sato S, Habara T, et al. Quality of life for patients with schizophrenia in a Japanese psychiatric hospital. Psychiatry Res. 2006; 144(1):49–56.
Gaite L, Vázquez-Barquero JL, Borra C, Ballesteros J, Schene A, Welcher B, et al. Quality of life in patients with schizophrenia in five European countries: The EPSILON study. Acta Psychiatr Scand. 2002; 105(4):283–92.
Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am J Psychiatry. 1998; 155(9):1196–201.
Norman RMG, Malla AK, McLean T, Voruganti LPN, Cortese L, McIntosh E, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand. 2000; 102(4):303–9.
Packer S, Husted J, Cohen S, Tomlinson G. Psychopathology and quality of life in schizophrenia. J Psychiatry Neurosci. 1997; 22(4):231–4.
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry. American Psychiatric Association; 1996; 153:321–30.
Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 1994; 36(11):717–25.
Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry. 2008; 32(1):280–7.
Meitzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologie deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology. 1996; 14:27s-33s.
Wegener S, Redoblado-Hodge MA, Wegener S, Redoblado-Hodge MA, Lucas S, Fitzgerald D, et al. Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. Aust New Zeal J Psychiatry. 2005; 39(6):487–92.
Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull. 1999; 25(1):173–82.
Aksaray G, Oflu S, Kaptanoǧlu C, Bal C. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog Neuro-Psychopharmacology Biol Psychiatry. 2002; 26(6):1217–9.
Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci. 1997.
(4):235–43. 22. Yanos PT, Moos RH. Determinants of functioning and well-being among individuals with schizophrenia: An integrated model. Clin Psychol Rev. 2007; 27(1):58–77.
Avison WR, Speechley KN. The discharged psychiatric patient: A review of social, socialpsychological, and psychiatric correlates of outcome. American Journal of Psychiatry. 1987; 144:10–8.
Ciompi L. Learning from outcome studies. Toward a comprehensive biological-psychosocial understanding of schizophrenia. Schizophr Res. 1988; 1(6):373–84.
Van Os J. The transdiagnostic dimension of psychosis: Implications for psychiatric nosology and research. Shanghai Arch Psychiatry. 2015; 27(2):82–6.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261–76.
Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP. Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res. 1994; 52(3):295–303.
Clark LK, Warman D, Lysaker PH. The relationships between schizophrenia symptom dimensions and executive functioning components. Schizophr Res. 2010; 124(1–3):169–75.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An Inventory for Measuring Depression. Arch Gen Psychiatry. 1961; 4(6):561–71.
Addington D, Addington J, Maticka-Tyndale E. Rating depression in schizophrenia. A comparison of a self-report and an observer report scale. J Nerv Ment Dis. 1993; 181(9):561–5.
Chemerinski E, Bowie C, Anderson H, Harvey PD. Depression in schizophrenia: Methodological artifact or distinct feature of the illness? J Neuropsychiatr. 2008; 20(4):431–40.
Spielberger CD, Gorsuch RL, Lushene RE. Cuestionario de ansiedad estado-rasgo adaptación española. 9th ed. TEA Ediciones, editor. Madrid; 2015. 39 p.
Giner J, Ibáñez E, Baca E, Bobes J, Leal C, Cervera S. Desarrollo del Cuestionario Sevilla de Calidad de Vida (CSCV). Actas Luso-Esp Neurol Psiquiatr Cienc Afines. 1997; 25(Supl 2):11–23.
Giner J, Bobes J, Cervera S, Leal C, Baca E, Ibáñez E. Impact of olanzapine on quality of life of patients with schizophrenia: One-year follow-up with the Seville Quality of Life Questionnaire. Actas Esp Psiquiatr. 2004; 32(1):1–7.
Gaviria AM, Queralt G, Martínez M, Novillo L, Salcedo N. Alteraciones neurocognitivas en la esquizofrenia. Análisis factorial. Med UPB. 2017; 36(2):123–32.
Mulet B, Valero J, Gutiérrez-Zotes A, Montserrat C, Cortés MJ, Jariod M, et al. Sustained and selective attention deficits as vulnerability markers to psychosis. Eur Psychiatry. 2007; 22(3):171–6.
Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with longacting risperidone for 1 year. Br J Psychiatry. 2005; 187(AUG.):131–6.
Lambert M, Naber D. Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004; 35:5–17.
Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, et al. The personal impact of schizophrenia in Europe. Schizophr Res. 2004; 69(2–3):125–32.
Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ. Optimizing treatment of schizophrenia enhancing affective/cognitive and depressive functioning. CNS Spectr. 2005; 10(2):1.
Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 1990; 41(8):892–7.
Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: A critical examination of the self-report methodology. Am J Psychiatry. 1997; 154(1):99–105.
Giner J, Ibáñez E, Cervera S, Sanmartín A, Caballero R. Subjective experience and quality of life in schizophrenia. Actas Esp Psiquiatr. 2001; 29(4):233–42.
Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: A meta-analysis. Schizophr Bull. 2007; 33(5):1225–37.
Kasckow JW, Twamley E, Mulchahey JJ, Carroll B, Sabai M, Strakowski SM, et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: Comparison with matched outpatients. Psychiatry Res. 2001; 103(1):69–78.
Lysaker P, Bell M. Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatr Scand. 1995; 91(3):205–8.
Racenstein JM, Harrow M, Reed R, Martin E, Herbener E, Penn DL. The relationship between positive symptoms and instrumental work functioning in schizophrenia: A 10 year follow-up study. Schizophr Res. 2002; 56(1–2):95–103.
Hofer A, Baumgartner S, Bodner T, Edlinger M, Hummer M, Kemmler G, et al. Patient outcomes in schizophrenia II: The impact of cognition. Eur Psychiatry. 2005; 20(5–6):395–402